In vivo genetic study reveals that seven CYP2A6 variants govern nicotine metabolism in European-Americans, indicating genotype predicts clearance rates.
Among European-Americans, seven polymorphisms in the CYP2A6 gene explain the majority of variability in the metabolism of nicotine to cotinine after oral administration. Parameters determined from this in-vivo experiment can be used to predict nicotine metabolism based on CYP2A6 genotype.
No takes yet. Share an insight, caveat, or question.
Bloom et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: